Sagent Pharmaceuticals (SGNT) Misses Q4 EPS Views; Guides FY16 Revenue Below Expectations

Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q4 EPS of ($0.55), $0.53 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $83.1 million versus the consensus estimate of $78.13 million.

GUIDANCE:

Sagent Pharmaceuticals sees FY2016 revenue of $325 - $365 million, versus the consensus of $378.1 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Enphase Energy (ENPH) Misses Q1 EPS by 7c, misses on guidance
• Mattel (MAT) Tops Q1 EPS by 7c, Revenue Misses, Offers Guidance